Mineralys Therapeutics, Inc. Common Stock MLYS
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T03:39:56.219Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T23:23:48.649282867Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T03:39:55.749994+00:00
Mineralys Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 12.76 | 166.7% | 26.2% | |||
| 25Δ | 13.71 | 141.2% | 20.6% | |||
| 30Δ | 14.65 | 115.6% | 15.1% | |||
| 35Δ | 17.64 | 77.2% | 12.2% | 15.23 | 102.8% | 12.1% |
| 40Δ | 17.25 | 74.4% | 10.5% | 15.60 | 97.3% | 10.7% |
| 45Δ | 16.94 | 72.1% | 9.3% | 15.96 | 91.8% | 9.2% |
| 50Δ | 16.64 | 69.8% | 8.1% | 16.33 | 86.4% | 7.7% |
| 55Δ | 16.33 | 67.5% | 7.0% | 16.70 | 80.9% | 6.2% |
| 60Δ | 16.02 | 65.2% | 5.8% | 17.06 | 75.5% | 4.7% |
| 65Δ | 15.71 | 62.9% | 4.7% | 17.43 | 70.0% | 3.2% |
| 70Δ | 15.40 | 60.6% | 3.5% | |||
| 75Δ | 15.09 | 58.3% | 2.3% | 23.28 | 189.6% | 4.9% |
| 80Δ | 24.18 | 177.9% | 3.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.76
- IV
- 166.7%
- B/E move
- 26.2%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.71
- IV
- 141.2%
- B/E move
- 20.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.65
- IV
- 115.6%
- B/E move
- 15.1%
35Δ
- Pseudo strike
- 17.64
- IV
- 77.2%
- B/E move
- 12.2%
- Pseudo strike
- 15.23
- IV
- 102.8%
- B/E move
- 12.1%
40Δ
- Pseudo strike
- 17.25
- IV
- 74.4%
- B/E move
- 10.5%
- Pseudo strike
- 15.60
- IV
- 97.3%
- B/E move
- 10.7%
45Δ
- Pseudo strike
- 16.94
- IV
- 72.1%
- B/E move
- 9.3%
- Pseudo strike
- 15.96
- IV
- 91.8%
- B/E move
- 9.2%
50Δ
- Pseudo strike
- 16.64
- IV
- 69.8%
- B/E move
- 8.1%
- Pseudo strike
- 16.33
- IV
- 86.4%
- B/E move
- 7.7%
55Δ
- Pseudo strike
- 16.33
- IV
- 67.5%
- B/E move
- 7.0%
- Pseudo strike
- 16.70
- IV
- 80.9%
- B/E move
- 6.2%
60Δ
- Pseudo strike
- 16.02
- IV
- 65.2%
- B/E move
- 5.8%
- Pseudo strike
- 17.06
- IV
- 75.5%
- B/E move
- 4.7%
65Δ
- Pseudo strike
- 15.71
- IV
- 62.9%
- B/E move
- 4.7%
- Pseudo strike
- 17.43
- IV
- 70.0%
- B/E move
- 3.2%
70Δ
- Pseudo strike
- 15.40
- IV
- 60.6%
- B/E move
- 3.5%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 15.09
- IV
- 58.3%
- B/E move
- 2.3%
- Pseudo strike
- 23.28
- IV
- 189.6%
- B/E move
- 4.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 24.18
- IV
- 177.9%
- B/E move
- 3.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 88.16% | |
| 85.33% | |
| 84.49% | |
| 84.01% | |
| 93.06% | |
| 91.06% | |
| 100.55% | |
| 105.47% | |
| 90.83% | |
| 96.99% |
Biotechnology
MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United…
More →MPLT
MapLight Therapeutics, Inc. is an innovative biotechnology company that is dedicated to developing groundbreaking therapies for complex neurological and psychiatric disorders.…
More →MRNA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases,…
More →MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human…
More →NAMS
NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its…
More →NAUT
Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome complexity. The company is…
More →